Artax Biopharma Closes Financing To Advance Clinical Stage First-In-Class Oral Immunomodulator To Treat T Cell-Mediated Diseases
Artax Biopharma Closes Financing To Advance Clinical Stage First-In-Class Oral Immunomodulator To Treat T Cell-Mediated Diseases
05/11/22, 8:08 AM
Location
cambridgeArtax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T Cell-mediated pathologies, today announces the close of a $26 million financing round to develop AX-158, the Company's first oral small molecule immunomodulating agent. New investors, Eli Lilly and Company and Sound Bioventures, participated alongside existing investors Advent Life Sciences, Columbus Venture Partners, Belinda Termeer and other Company shareholders.
Company Info
Location
cambridge, maryland, united states
Additional Info
Artax Biopharma is a clinical-stage biotechnology company transforming T Cell-mediated disease treatment by developing innovative small molecules that modulate the immune system. Artax science holds broad potential to treat T Cell-mediated diseases such as autoimmune diseases; induced T cell pathologies (such as acute graft-versus-host disease and immune-oncology treatment-related adverse events); and T Cell malignancies, while simultaneously allowing the body to fight foreign pathogens. For more information, please visit: www.artaxbiopharma.com.